CN111228249A - Antioxidant composition, preparation method and application - Google Patents
Antioxidant composition, preparation method and application Download PDFInfo
- Publication number
- CN111228249A CN111228249A CN202010133507.XA CN202010133507A CN111228249A CN 111228249 A CN111228249 A CN 111228249A CN 202010133507 A CN202010133507 A CN 202010133507A CN 111228249 A CN111228249 A CN 111228249A
- Authority
- CN
- China
- Prior art keywords
- antioxidant composition
- astaxanthin
- oil
- sucrose
- polyglycerol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 91
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 89
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 84
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 235000006708 antioxidants Nutrition 0.000 claims abstract description 83
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 58
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims abstract description 51
- 239000001168 astaxanthin Substances 0.000 claims abstract description 51
- 235000013793 astaxanthin Nutrition 0.000 claims abstract description 51
- 229940022405 astaxanthin Drugs 0.000 claims abstract description 51
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims abstract description 51
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims abstract description 35
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims abstract description 35
- 235000012661 lycopene Nutrition 0.000 claims abstract description 35
- 229960004999 lycopene Drugs 0.000 claims abstract description 35
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims abstract description 35
- 239000001751 lycopene Substances 0.000 claims abstract description 35
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims abstract description 35
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 28
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 28
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 28
- 229940046009 vitamin E Drugs 0.000 claims abstract description 28
- 239000011709 vitamin E Substances 0.000 claims abstract description 28
- 239000000463 material Substances 0.000 claims abstract description 16
- 239000007788 liquid Substances 0.000 claims abstract description 4
- 239000007787 solid Substances 0.000 claims abstract description 4
- 239000003921 oil Substances 0.000 claims description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 235000018102 proteins Nutrition 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 150000004676 glycans Chemical class 0.000 claims description 15
- 229930006000 Sucrose Natural products 0.000 claims description 14
- 239000000839 emulsion Substances 0.000 claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- 239000005720 sucrose Substances 0.000 claims description 14
- -1 sucrose ester Chemical class 0.000 claims description 14
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 12
- 229920001282 polysaccharide Polymers 0.000 claims description 12
- 239000005017 polysaccharide Substances 0.000 claims description 12
- 239000004615 ingredient Substances 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 229940049964 oleate Drugs 0.000 claims description 10
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 8
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 8
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 claims description 8
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims description 8
- 229940070765 laurate Drugs 0.000 claims description 8
- 150000003904 phospholipids Chemical class 0.000 claims description 8
- 229920005862 polyol Polymers 0.000 claims description 8
- 239000000600 sorbitol Substances 0.000 claims description 8
- 239000003381 stabilizer Substances 0.000 claims description 8
- 150000005846 sugar alcohols Polymers 0.000 claims description 8
- 241000196324 Embryophyta Species 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 6
- 239000003925 fat Substances 0.000 claims description 6
- 239000000194 fatty acid Substances 0.000 claims description 6
- 229930195729 fatty acid Natural products 0.000 claims description 6
- 229950008882 polysorbate Drugs 0.000 claims description 6
- 229920000136 polysorbate Polymers 0.000 claims description 6
- 238000001694 spray drying Methods 0.000 claims description 5
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 claims description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 4
- 108010073771 Soybean Proteins Proteins 0.000 claims description 4
- 241000209140 Triticum Species 0.000 claims description 4
- 235000021307 Triticum Nutrition 0.000 claims description 4
- GCSPRLPXTPMSTL-IBDNADADSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GCSPRLPXTPMSTL-IBDNADADSA-N 0.000 claims description 4
- 235000010323 ascorbic acid Nutrition 0.000 claims description 4
- 239000011668 ascorbic acid Substances 0.000 claims description 4
- 229960005070 ascorbic acid Drugs 0.000 claims description 4
- 229960001484 edetic acid Drugs 0.000 claims description 4
- 235000010350 erythorbic acid Nutrition 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 229940026239 isoascorbic acid Drugs 0.000 claims description 4
- 239000003094 microcapsule Substances 0.000 claims description 4
- 229940105132 myristate Drugs 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 4
- 150000003077 polyols Chemical class 0.000 claims description 4
- 235000019710 soybean protein Nutrition 0.000 claims description 4
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims description 4
- 229920001661 Chitosan Polymers 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- 241000238557 Decapoda Species 0.000 claims description 3
- 229920002907 Guar gum Polymers 0.000 claims description 3
- 235000010489 acacia gum Nutrition 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 239000007789 gas Substances 0.000 claims description 3
- 239000003292 glue Substances 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 239000000665 guar gum Substances 0.000 claims description 3
- 235000010417 guar gum Nutrition 0.000 claims description 3
- 229960002154 guar gum Drugs 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- UHGGERUQGSJHKR-VCDGYCQFSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;octadecanoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCCCCCCCCCCCC(O)=O UHGGERUQGSJHKR-VCDGYCQFSA-N 0.000 claims description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 2
- 244000215068 Acacia senegal Species 0.000 claims description 2
- HDLNSTQYXPTXMC-UHFFFAOYSA-N Astaxanthin-diacetat Natural products O=C1C(OC(=O)C)CC(C)(C)C(C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC=2C(CC(C(=O)C=2C)OC(C)=O)(C)C)=C1C HDLNSTQYXPTXMC-UHFFFAOYSA-N 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 claims description 2
- 239000011627 DL-alpha-tocopherol Substances 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 108010022355 Fibroins Proteins 0.000 claims description 2
- 229920000084 Gum arabic Polymers 0.000 claims description 2
- 241000168517 Haematococcus lacustris Species 0.000 claims description 2
- 235000007688 Lycopersicon esculentum Nutrition 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 239000004368 Modified starch Substances 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 240000003768 Solanum lycopersicum Species 0.000 claims description 2
- HFJHNGKIVAKCIW-UHFFFAOYSA-N Stearyl monoglyceridyl citrate Chemical compound OCC(O)CO.OC(=O)CC(O)(CC(O)=O)CC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O HFJHNGKIVAKCIW-UHFFFAOYSA-N 0.000 claims description 2
- 108010046377 Whey Proteins Proteins 0.000 claims description 2
- 102000007544 Whey Proteins Human genes 0.000 claims description 2
- FOLJTMYCYXSPFQ-CJKAUBRRSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-(octadecanoyloxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl octadecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)O[C@@H]1O[C@@]1(COC(=O)CCCCCCCCCCCCCCCCC)[C@@H](O)[C@H](O)[C@@H](CO)O1 FOLJTMYCYXSPFQ-CJKAUBRRSA-N 0.000 claims description 2
- ZPVGIKNDGJGLCO-VGAMQAOUSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZPVGIKNDGJGLCO-VGAMQAOUSA-N 0.000 claims description 2
- OCRUMFQGIMSFJR-FSAWCSQFSA-N [(2s,3s,4r,5r)-4-hydroxy-5-(hydroxymethyl)-3-[(z)-octadec-9-enoyl]oxy-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl (z)-octadec-9-enoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCC\C=C/CCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC OCRUMFQGIMSFJR-FSAWCSQFSA-N 0.000 claims description 2
- SZYSLWCAWVWFLT-UTGHZIEOSA-N [(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octadecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O SZYSLWCAWVWFLT-UTGHZIEOSA-N 0.000 claims description 2
- UEYVMVXJVDAGBB-ZHBLIPIOSA-N [(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl tetradecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O UEYVMVXJVDAGBB-ZHBLIPIOSA-N 0.000 claims description 2
- 239000000205 acacia gum Substances 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 239000000783 alginic acid Substances 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 229960001126 alginic acid Drugs 0.000 claims description 2
- 150000004781 alginic acids Chemical class 0.000 claims description 2
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 2
- 235000010418 carrageenan Nutrition 0.000 claims description 2
- 239000000679 carrageenan Substances 0.000 claims description 2
- 229920001525 carrageenan Polymers 0.000 claims description 2
- 229940113118 carrageenan Drugs 0.000 claims description 2
- 239000005018 casein Substances 0.000 claims description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 2
- 235000021240 caseins Nutrition 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 claims description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims description 2
- MPVXINJRXRIDDB-VCDGYCQFSA-N dodecanoic acid;(2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCCCCCC(O)=O MPVXINJRXRIDDB-VCDGYCQFSA-N 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 235000019426 modified starch Nutrition 0.000 claims description 2
- 229920001206 natural gum Polymers 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 239000000419 plant extract Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 2
- 235000013824 polyphenols Nutrition 0.000 claims description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 2
- 235000021119 whey protein Nutrition 0.000 claims description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 2
- 239000004318 erythorbic acid Substances 0.000 claims 1
- 235000013311 vegetables Nutrition 0.000 claims 1
- 239000000969 carrier Substances 0.000 abstract description 9
- 230000003647 oxidation Effects 0.000 abstract description 7
- 238000007254 oxidation reaction Methods 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 230000003851 biochemical process Effects 0.000 abstract description 2
- 230000004377 improving vision Effects 0.000 abstract description 2
- 235000019198 oils Nutrition 0.000 description 17
- 239000012071 phase Substances 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 150000003254 radicals Chemical class 0.000 description 10
- 230000006378 damage Effects 0.000 description 9
- 210000001508 eye Anatomy 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 210000004379 membrane Anatomy 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 239000003208 petroleum Substances 0.000 description 5
- 239000003012 bilayer membrane Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000011990 functional testing Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 210000004087 cornea Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000037394 skin elasticity Effects 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- ARIWANIATODDMH-UHFFFAOYSA-N Lauric acid monoglyceride Natural products CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 210000005081 epithelial layer Anatomy 0.000 description 2
- 238000005187 foaming Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 235000010378 sodium ascorbate Nutrition 0.000 description 2
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 2
- 229960005055 sodium ascorbate Drugs 0.000 description 2
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 2
- 229940083466 soybean lecithin Drugs 0.000 description 2
- QHZLMUACJMDIAE-UHFFFAOYSA-N 1-monopalmitoylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)CO QHZLMUACJMDIAE-UHFFFAOYSA-N 0.000 description 1
- GUOCOOQWZHQBJI-UHFFFAOYSA-N 4-oct-7-enoxy-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)OCCCCCCC=C GUOCOOQWZHQBJI-UHFFFAOYSA-N 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108010033929 calcium caseinate Proteins 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002390 cell membrane structure Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940096898 glyceryl palmitate Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000002013 hydrophilic interaction chromatography Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000009013 pigment accumulation Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000002569 water oil cream Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
Abstract
The invention discloses an antioxidant composition, a preparation method and application thereof, wherein the antioxidant composition comprises the following components in parts by weight: 1-500 parts of astaxanthin, 1-500 parts of lycopene, 1-500 parts of vitamin E and 1-5000 parts of auxiliary materials. The antioxidant composition provided by the invention can be liquid or solid; can be taken orally or externally; can be used alone or added into other carriers as effective component. The antioxidant composition has the functions of reducing the oxidation pressure of a human body and improving the total antioxidant capacity of the human body; can prevent and inhibit oxidation of cell structure, inhibit harmful biochemical process caused by oxidation pressure in cell, and has effects of protecting skin, improving skin condition, protecting eye, and improving vision.
Description
Technical Field
The invention provides an oral or external antioxidant composition, and particularly relates to an antioxidant composition, a preparation method and application, which can be applied to the technical fields of food, medicines, health-care medicines, cosmetics and skin care products, in particular to a product for preventing and inhibiting damages of a human body caused by an oxidation process.
Background
The free radical is an atom or a group which is formed by the homogeneous splitting of a covalent bond and has unpaired electrons, and has strong oxidizability. The metabolic process of the human body is a process of oxidatively decomposing nutrients to obtain energy and required nutrients, and in this process, radicals are generated. In addition, ultraviolet rays or other high-energy rays destroy covalent bonds to generate radicals. After accumulation in the body, free radicals can cause damage to cells, including organelles, cell membrane structures, DNA, and intercellular substrates, such as collagen. In addition to direct injury to the human body, excessive intracellular free radical concentration can also cause inflammation and indirect injury to the human body. Eyes and skin, as organs in which the human body directly contacts the outside, are exposed to sunlight (ultraviolet rays) for a long time. The free radicals produced by the process damage the structures inside the eyeball (cornea, lens, retina, choroid, etc.) to cause eye diseases; it also causes photoaging of the skin, resulting in reduced skin moisture, loss of elasticity, pigment accumulation and wrinkling, and in severe cases, may also cause skin cancer. Therefore, proper supplementation of antioxidants can prevent and inhibit damage of free radicals to the human body, particularly damage to the skin and eyes.
Astaxanthin, the english Astaxanthin, chemical name 3, 3 '-dihydroxy-4, 4' -diketo β -carotene, is one of the terpenes, and carotenoids, is a natural antioxidant known to exist in nature, which has the strongest antioxidant capacity from a chemical point of view, the specific chemical structure of Astaxanthin enables it to span a biological membrane structure (e.g., cell membrane) and simultaneously remove free radicals on both sides of the biological membrane structure, while Astaxanthin can serve as an electron transport channel across the biological membrane, contributing electrons obtained from one side of the biological membrane to free radicals on the other side, so that an antioxidant which cannot pass through the biological membrane structure at all can also scavenge free radicals on the other side of the biological membrane.
Therefore, an antioxidant composition, a preparation method and an application thereof are needed when astaxanthin, lycopene and vitamin E are used in combination.
Disclosure of Invention
In order to overcome the defects in the prior art, the invention provides an antioxidant composition, a preparation method and application.
In order to solve the technical problems, the invention provides the following technical scheme:
the invention provides an antioxidant composition, which comprises the following components in parts by weight: 1-500 parts of astaxanthin, 1-500 parts of lycopene, 1-500 parts of vitamin E and 1-5000 parts of auxiliary materials.
In a preferred embodiment of the present invention, the astaxanthin is one or more of natural astaxanthin ester extracted from Haematococcus pluvialis, free astaxanthin extracted from bacteria and yeast, chemically synthesized astaxanthin, and natural astaxanthin extracted from shrimp and crab; lycopene refers to natural lycopene extracted from tomato; the vitamin E refers to one or more of natural vitamin E, semisynthetic vitamin E, synthetic vitamin E and derivatives of the three compounds from any source.
As a preferred technical scheme of the invention, the auxiliary materials comprise one or more of glue, polysaccharide, glycan, protein, peptide, sucrose ester, polyol fatty acid ester, ascorbic acid and salts thereof, isoascorbic acid and salts thereof, ethylene diamine tetraacetic acid, fat, oil, phospholipid, polyol and stabilizer.
As a preferred technical scheme of the invention, the gum is natural gum extracted from animals and plants, and the gum is one of carrageenan, Arabic gum, guar gum and pectin; the polysaccharide is one or more of natural polysaccharide, polysaccharide and its processed derivatives, modified starch, dextrin, cyclodextrin, chitosan, alginic acid and its derivatives extracted from animals and plants; the protein refers to natural protein extracted from animals and plants, and is one or more of soybean protein isolate, wheat protein isolate, whey protein, casein and its acid salt, and collagen; the peptide is obtained by partially decomposing natural protein, and is one or more of soybean protein peptide, wheat protein peptide and fibroin peptide.
As a preferred technical scheme of the invention, the sucrose ester is one or more of sucrose laurate, sucrose dilaurate, sucrose stearate, sucrose distearate, sucrose palmitate, sucrose dipalmitate, sucrose myristate, sucrose dimyristate, sucrose oleate and sucrose dioleate; the polyalcohol fatty acid ester is one or more of glycerol-6 oleate, polyglycerol-6 stearate, polyglycerol-6 palmitate, polyglycerol-6 myristate, polyglycerol-6 laurate, polyglycerol-10 oleate, polyglycerol-10 stearate, polyglycerol-10 palmitate, polyglycerol-10 myristate, polyglycerol-10 laurate, glycerol stearate citrate, polyglycerol-10 distearate, sorbitol stearate, sorbitol laurate, sorbitol palmitate, sorbitol oleate, polysorbate laurate, polysorbate palmitate and polysorbate oleate.
As a preferred technical scheme of the invention, the fat and oil refer to any animal, plant, mineral source and chemically synthesized fat and oil substances, and the fat and oil can also comprise one or more of monoglyceride, diglyceride and triglyceride; the polyalcohol is one or more of glycerol, diglycerol, propylene glycol, butanediol, polyethylene glycol, sorbitol, mannitol, and dipropylene glycol; the stabilizer is oil soluble substance, and is one or more of plant extract and natural polyphenol.
As a preferred technical scheme, the invention provides a preparation method of an antioxidant composition, which comprises the following steps:
s1, preparation of an oil phase containing effective functional components:
heating fat and oil to 30-80 deg.c, and dissolving astaxanthin, lycopene, vitamin E and one or several of phosphatide, polyol, stabilizer, sucrose ester and polyol fatty acid ester as supplementary material; wherein, the astaxanthin accounts for 0.5 to 25 percent of the total weight of the oil phase, the lycopene accounts for 0.5 to 25 percent of the total weight of the oil phase, and the vitamin E accounts for 0.5 to 25 percent of the total weight of the oil phase; the weight ratio of the fat to the oil to the astaxanthin is 1: 2-10: 1, the weight ratio of the phospholipid to the astaxanthin is 5: 1-1: 5, the weight ratio of the polyalcohol to the astaxanthin is 20: 1-1: 1, and the weight ratio of other components of the auxiliary material to the astaxanthin is 1: 100-100: 1;
s2, preparation of an embedded water phase:
mixing one or more of adjuvants including gum, polysaccharide, protein, peptide, ascorbic acid and its salt, isoascorbic acid and its salt, ethylenediaminetetraacetic acid, polyalcohol, and stabilizer with water, and dissolving; wherein the weight ratio of one or more of glue, polysaccharide, glycan, protein and peptide to water is 2: 1-1: 10, and the weight ratio of other components of the auxiliary material to water is 1: 5-1: 200;
s3, mixing and homogenizing:
mixing the oil phase containing the effective functional ingredients prepared in the step S1 and the embedded water phase prepared in the step S2 to form oil-water or water-oil dispersed emulsion containing the main functional ingredients, wherein the weight ratio of the oil phase containing the effective functional ingredients to the embedded water phase is 30: 1-1: 30, homogenizing to ensure that the average particle size of the oil-water or water-oil dispersed emulsion of the generated mixture is 10 nm-10 um, and preparing the liquid antioxidant composition; wherein, the homogenizing method in step S3 includes one or more of high-speed homogenizing, high-pressure homogenizing, ultrasonic homogenizing, and vibration homogenizing.
As a preferred technical scheme of the invention, the invention also provides a preparation method of the antioxidant composition, which further comprises the following steps:
s4, drying:
drying the oil-water or water-oil dispersed emulsion containing the main functional components prepared in the step S3 to prepare a microcapsule antioxidant composition; wherein, the drying method in the step S4 is spray drying, the inlet air temperature used in the spray drying is not more than 200 ℃, and nitrogen is used as the drying gas.
The invention provides application of an antioxidant composition as a preferable technical scheme, which is characterized in that the antioxidant composition is added into other carriers to be used as an ingredient, the carriers comprise one of oily fluid carriers, aqueous fluid carriers, emulsion carriers and solid carriers, and the carriers are single substances or mixtures.
The invention has the beneficial effects that: the antioxidant composition prepared by the preparation method of the antioxidant composition can be liquid or solid; can be taken orally or externally; can be used alone or added into other carriers as effective component. The antioxidant composition provided by the invention has the functions of reducing the oxidation pressure of a human body and improving the total antioxidant capacity of the human body; can prevent and inhibit oxidation of cell structure, inhibit harmful biochemical process caused by oxidation pressure in cell, and has effects of protecting skin, improving skin condition, protecting eye, and improving vision.
The antioxidant composition provided by the invention combines astaxanthin, lycopene and vitamin E as main functional components. Experimental data show that through the synergistic effect of the three main functional components, the antioxidant effect of the antioxidant composition provided by the invention is superior to the mathematical addition of the effects of the three main functional components when used alone or in combination of two main functional components. In addition, by adding auxiliary materials and a special preparation method, the antioxidant capacity of the antioxidant composition provided by the invention is higher than that of the antioxidant effect of the antioxidant composition which is prepared by directly mixing the three main functional components. The antioxidant composition provided by the invention obviously improves the antioxidant effect of the three main functional components under the condition of not increasing the use amount of the main functional components.
In addition, the three main functional components in the antioxidant composition provided by the invention are all oil-soluble, insoluble or insoluble in water. The antioxidant composition provided by the invention can be directly used in an oil-soluble form. In addition, the antioxidant composition provided by the invention utilizes the auxiliary materials to carry out nano-scale and micron-scale liquid phase embedding on the main functional components through regulation and control of the addition amount of the auxiliary materials and a unique mixing and homogenizing process; the main functional components are subjected to nano-scale and micron-scale solid-phase embedding by utilizing the auxiliary materials through regulation and control of the addition amount of the auxiliary materials, unique mixing and homogenizing processes and unique drying processes. Therefore, the three main functional components can be subjected to water-soluble treatment, so that the three main functional components can be dispersed in an aqueous solution, and the storage stability of the three main functional components is remarkably improved. Meanwhile, the antioxidant composition provided by the invention can be taken orally or used externally, so that the application scenes of main functional components of the antioxidant composition are widened. The antioxidant composition provided by the invention can improve the whole antioxidant capacity of a human body when being taken orally, and can improve the antioxidant capacity of certain organs such as skin and eyes in a targeted manner while not obviously influencing the whole antioxidant capacity of the human body when being used externally. According to the invention, through the addition of the auxiliary materials and the special preparation method, the nano-scale and micron-scale embedding of the main functional components is realized, and the biological absorptivity of the three main functional components in the antioxidant composition is remarkably improved through the addition of other components in the auxiliary materials.
Detailed Description
The following description of the preferred embodiments of the present invention is provided for the purpose of illustration and description, and is in no way intended to limit the invention.
Example 1: preparation of the antioxidant composition of the present invention
Mixing 45g of olive oil with 45g of glycerin, heating to 50 deg.C, dissolving 12g of astaxanthin, 5g of lycopene and 5g of vitamin E, adding 10g of soybean lecithin and 2g of glycerol laurate, and dissolving to form an oil phase containing main functional components.
3g of sucrose laurate, 3g of sorbitol, 2g of polyglycerol-10 laurate, 1g of sodium ascorbate, 5g of gum arabic, 90g of maltodextrin, 80g of sodium starch octenylsuccinate were dissolved in 600g of water to form an embedded aqueous phase. The raw materials are all food-grade raw materials sold in the market.
Mixing the oil phase and the water phase, making the mixture into coarse emulsion with high-speed shearing emulsifying machine (Wiggens, D-500, China), and making into emulsion with high-pressure homogenizer (ATS, AH-NANO, China).
The emulsion is dried by using nitrogen as drying gas by a spray drying method (Yacheng, YC-501, China; inlet air temperature 120 ℃, outlet air temperature 80 ℃) and is prepared into microcapsules. The microcapsule is the antioxidant composition of the invention.
The following table shows the comparison of the storage stability (lower degradation rate, higher storage stability) of astaxanthin, lycopene, vitamin E and the untreated mixture of the three components in the antioxidant composition of the invention prepared as described in example 1, under the test conditions of 30 days of sealed storage at 50 ℃:
the table shows that the antioxidant composition can remarkably improve the storage stability of three effective components of astaxanthin, lycopene and vitamin E.
Example 2: preparation of the antioxidant composition of the present invention
Mixing 40g safflower seed oil with 25g glyceryl palmitate, heating to 50 deg.C, dissolving 8g astaxanthin, 6g lycopene, and 3g natural vitamin E, adding 12g soybean lecithin, and dissolving to form oil phase containing main functional components.
Sucrose laurate (5 g), sorbitol (2 g), polyglycerol-10 laurate (1 g), sodium ascorbate (1 g), guar gum (5 g), calcium caseinate (5 g), chitosan (30 g) and maltodextrin (50 g) were dissolved in water (600 g) to form an aqueous phase. The raw materials are all food-grade raw materials sold in the market.
Mixing the oil phase and the water phase, preparing the mixture into coarse emulsion by using a high-speed shearing emulsifying machine (Wiggens, D-500, China), and preparing the coarse emulsion into water-oil emulsion by using a high-pressure homogenizer (ATS, AH-NANO, China). The emulsion is the antioxidant composition.
Application example 1: the antioxidant composition of the invention is subjected to relevant functional tests.
The antioxidant composition of the present invention prepared in example 2 was used while comparing the antioxidant capacity against unprocessed equal amounts of astaxanthin, lycopene, vitamin E, combinations of two thereof and mixtures of the three. Phospholipid bilayer membranes extracted from mouse liver were used as models of biofilm structure. To 9 groups (3 samples per group) of culture media containing phospholipid bilayer membranes were added: a composition which does not contain effective functional components but contains other components of the antioxidant composition of the invention prepared in example 2, unprocessed equivalent amounts of astaxanthin, lycopene, vitamin E, combinations of two of them and mixtures of the three, and the antioxidant composition of the invention prepared in example 2. The amounts added were such that the concentrations of astaxanthin, lycopene and vitamin E were the same in each sample containing the corresponding components (astaxanthin 80ng/mL, lycopene 60ng/mL, vitamin E30 ng/mL; dissolved in DMSO, final DMSO concentrations were below 10 uM).
For measurement, chlorophyll was added to each sample, and the oxidative stress on the biofilm structure was simulated by irradiation with visible light of 430nm wavelength to generate superoxide radicals. The time of foaming (breakdown of the membrane structure) of the phospholipid bilayer membrane was observed by a microscope, and the longer the delay time of foaming, the higher the antioxidant property of the additive.
The following table shows the time for which the phospholipid bilayer membranes of the 9 control groups were bubbled:
the above table shows that the antioxidant composition combines three main functional components of astaxanthin, lycopene and vitamin E, and the antioxidant effect of the antioxidant composition exceeds the mathematical sum of the effects of the three components which are used independently or are used in a pairwise matching way. In addition, through the addition of auxiliary materials and a special preparation method, the antioxidant capacity of the antioxidant composition is higher than that of the antioxidant effect of the antioxidant composition prepared by directly mixing the three main functional components.
Application example 2: the antioxidant composition of the invention is subjected to relevant functional tests.
The antioxidant composition of the present invention prepared in example 1 was orally administered to mice, and the contents of astaxanthin and lycopene in the serum of the mice were measured in comparison with a mixture of astaxanthin, lycopene and vitamin E which was not prepared according to the formulation and preparation method of the present invention. Adult mice (n ═ 40) were divided into two groups. 3g of the antioxidant composition of the invention prepared in example 1 was orally administered to a group, and a control group was orally administered a mixture of untreated astaxanthin, lycopene, vitamin E with the same content of active ingredients. Serum was collected 3, 6, and 9 hours after administration, and the serum was analyzed for astaxanthin and lycopene contents.
The method for measuring the content of the serum astaxanthin and the lycopene comprises the following steps: adding petroleum ether with a volume ratio of 1: 1 into the serum, and extracting free astaxanthin and lycopene into the petroleum ether. The petroleum ether and the aqueous phase containing acetone were separated by centrifugation, and the petroleum ether was carefully removed and placed in a clean container. Petroleum ether was evaporated at low temperature using nitrogen and the dried residue was dissolved in high purity acetone in a volume ratio of 1: 1 to acetone diluent. 20uL of the above highly pure acetone solution was analyzed by high performance liquid chromatography (Infinity 1260, Agilent, USA; column Infinity Lab 120 HILIC 2.1X150mm, 2.7um, Agilent, USA; mobile phase 82: 18 hexane: acetone; flow rate 1 mL/min). And finally, the concentrations of the astaxanthin and the lycopene are calculated according to standard curves of the astaxanthin and the lycopene (the astaxanthin standard is more than 98 percent, the lycopene is more than 99 percent, sigma and Germany).
The following table shows the astaxanthin and lycopene contents in the mouse serum:
the table shows that the antioxidant composition can effectively improve the biological absorptivity of three main functional components of astaxanthin, lycopene and vitamin E.
Application example 3: the antioxidant composition of the invention is subjected to relevant functional tests. Mice were orally administered the antioxidant composition of the present invention prepared in example 1 to control the degree of corneal damage after UVB irradiation of eyes in a non-use group. Adult mice (n ═ 40) were divided into 3 groups. One group of the antioxidant composition of the present invention prepared in example 1 was orally administered, another group of the mixture of untreated astaxanthin, lycopene, vitamin E with the same content of effective ingredients was orally administered, and the last group used a composition containing no effective functional ingredient but other ingredients of the antioxidant composition of the present invention prepared in example 2. The antioxidant composition of the present invention prepared in example 1 of the use group was used in an amount of 4g per day, once a day in the morning. After 3 weeks, the eyes of the mice were subjected to UVB irradiation with a wavelength of 290-320nm at an intensity of 400mJ/cm2 for a period of 5 minutes. Mice were depalletized 24 hours after irradiation, and eyeball sections were prepared, and the cornea in the sections was observed by a microscope to analyze the corneal epithelial layer thickness and the corneal apoptosis rate.
The following table shows the thickness of the corneal epithelial layer (lower thickness indicates greater damage) and the apoptosis rate of corneal cells (higher apoptosis rate, more severe damage) in each group of eye sections after UVB irradiation:
as can be seen from the above table, the antioxidant composition of the present invention can effectively inhibit the damage of Ultraviolet (UVB) rays to the cornea of the eye, and the effect is higher than that of the mixture of astaxanthin, lycopene and vitamin E which is not prepared according to the formula and the preparation method of the present invention.
Application example 4: the antioxidant composition of the invention is subjected to relevant functional tests.
Volunteers applied to facial skin the antioxidant composition of the present invention prepared in example 2 was compared to skin conditions of the unused group. Volunteers (n ═ 30), women, between ages 35-55, were divided into two groups of similar average ages. One group of the compositions used in the antioxidant composition of the present invention prepared in example 2, and the other group of the compositions used in the antioxidant composition of the present invention prepared in example 2, which do not contain effective functional components, but contain other components, and have the same color. The volunteers applied the above two compositions in groups, 2mL each time, evenly applied to the face, and washed the face after 20 minutes, once in the morning and once in the evening. Evaluation of skin condition was performed after 3 weeks, and the evaluation contents included: 1) a subjective questionnaire, the questionnaire content comprising: skin wetness, skin elasticity, skin tone, skin wrinkles; -5 to 5 points, -5 points with marked deterioration, 0 points without change, and 5 points with marked improvement; 2) measuring the moisture content and the elasticity of the skin by using a commercially available skin measuring instrument; 3) the dermatologist, and the evaluation indexes comprise: skin elasticity, skin tone, skin wrinkles; a score of-5 to 5, a score of-5 with marked deterioration, a score of 0 with no change, and a score of 5 with marked improvement.
The following table is the results of the skin condition assessment:
as can be seen from the above table, the antioxidant composition of the present invention has significant improvement effects on skin conditions when used externally, including increasing skin moisture content, increasing skin elasticity, improving skin tone, and reducing skin wrinkles.
Finally, it should be noted that: although the present invention has been described in detail with reference to the foregoing embodiments, it will be apparent to those skilled in the art that changes may be made in the embodiments and/or equivalents thereof without departing from the spirit and scope of the invention. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (9)
1. The antioxidant composition is characterized by comprising the following components in parts by weight: 1-500 parts of astaxanthin, 1-500 parts of lycopene, 1-500 parts of vitamin E and 1-5000 parts of auxiliary materials.
2. The antioxidant composition of claim 1, wherein astaxanthin is one or more of natural astaxanthin ester extracted from Haematococcus pluvialis, free astaxanthin extracted from bacteria and yeasts, chemically synthesized astaxanthin, natural astaxanthin extracted from shrimps and crabs; lycopene refers to natural lycopene extracted from tomato; the vitamin E refers to one or more of natural vitamin E, semisynthetic vitamin E, synthetic vitamin E and derivatives of the three compounds from any source.
3. The antioxidant composition as claimed in claim 1, wherein the adjuvant comprises one or more of gum, polysaccharide, protein, peptide, sucrose ester, polyol fatty acid ester, ascorbic acid and its salt, erythorbic acid and its salt, ethylene diamine tetraacetic acid, fat, oil, phospholipid, polyol, and stabilizer.
4. The antioxidant composition as claimed in claim 3, wherein the gum is natural gum extracted from animal and plant, and the gum is one of carrageenan, gum arabic, guar gum and pectin; the polysaccharide is one or more of natural polysaccharide, polysaccharide and its processed derivatives, modified starch, dextrin, cyclodextrin, chitosan, alginic acid and its derivatives extracted from animals and plants; the protein refers to natural protein extracted from animals and plants, and is one or more of soybean protein isolate, wheat protein isolate, whey protein, casein and its acid salt, and collagen; the peptide is obtained by partially decomposing natural protein, and is one or more of soybean protein peptide, wheat protein peptide and fibroin peptide.
5. The antioxidant composition as claimed in claim 3, wherein the sucrose ester is one or more of sucrose laurate, sucrose dilaurate, sucrose stearate, sucrose distearate, sucrose palmitate, sucrose dipalmitate, sucrose myristate, sucrose dimyristate, sucrose oleate, sucrose dioleate; the polyalcohol fatty acid ester is one or more of glycerol-6 oleate, polyglycerol-6 stearate, polyglycerol-6 palmitate, polyglycerol-6 myristate, polyglycerol-6 laurate, polyglycerol-10 oleate, polyglycerol-10 stearate, polyglycerol-10 palmitate, polyglycerol-10 myristate, polyglycerol-10 laurate, glycerol stearate citrate, polyglycerol-10 distearate, sorbitol stearate, sorbitol laurate, sorbitol palmitate, sorbitol oleate, polysorbate laurate, polysorbate palmitate and polysorbate oleate.
6. The antioxidant composition as claimed in claim 3, wherein the fat and oil are any animal, vegetable, mineral, and chemically synthesized fats and oils, and may further comprise one or more of monoglyceride, diglyceride, and triglyceride; the polyalcohol is one or more of glycerol, diglycerol, propylene glycol, butanediol, polyethylene glycol, sorbitol, mannitol, and dipropylene glycol; the stabilizer is oil soluble substance, and is one or more of plant extract and natural polyphenol.
7. The preparation method of the antioxidant composition is characterized by comprising the following steps:
s1, preparation of an oil phase containing effective functional components:
heating fat and oil to 30-80 deg.c, and dissolving astaxanthin, lycopene, vitamin E and one or several of phosphatide, polyol, stabilizer, sucrose ester and polyol fatty acid ester as supplementary material; wherein, the astaxanthin accounts for 0.5 to 25 percent of the total weight of the oil phase, the lycopene accounts for 0.5 to 25 percent of the total weight of the oil phase, and the vitamin E accounts for 0.5 to 25 percent of the total weight of the oil phase; the weight ratio of the fat to the oil to the astaxanthin is 1: 2-10: 1, the weight ratio of the phospholipid to the astaxanthin is 5: 1-1: 5, the weight ratio of the polyalcohol to the astaxanthin is 20: 1-1: 1, and the weight ratio of other components of the auxiliary material to the astaxanthin is 1: 100-100: 1;
s2, preparation of an embedded water phase:
mixing one or more of adjuvants including gum, polysaccharide, protein, peptide, ascorbic acid and its salt, isoascorbic acid and its salt, ethylenediaminetetraacetic acid, polyalcohol, and stabilizer with water, and dissolving; wherein the weight ratio of one or more of glue, polysaccharide, glycan, protein and peptide to water is 2: 1-1: 10, and the weight ratio of other components of the auxiliary material to water is 1: 5-1: 200;
s3, mixing and homogenizing:
mixing the oil phase containing the effective functional ingredients prepared in the step S1 and the embedded water phase prepared in the step S2 to form oil-water or water-oil dispersed emulsion containing the main functional ingredients, wherein the weight ratio of the oil phase containing the effective functional ingredients to the embedded water phase is 30: 1-1: 30, homogenizing to ensure that the average particle size of the oil-water or water-oil dispersed emulsion of the generated mixture is 10 nm-10 um, and preparing the liquid antioxidant composition; wherein, the homogenizing method in step S3 includes one or more of high-speed homogenizing, high-pressure homogenizing, ultrasonic homogenizing, and vibration homogenizing.
8. The preparation method of the antioxidant composition is characterized by further comprising the following steps:
s4, drying:
drying the oil-water or water-oil dispersed emulsion containing the main functional components prepared in the step S3 to prepare a microcapsule antioxidant composition; wherein, the drying method in the step S4 is spray drying, the inlet air temperature used in the spray drying is not more than 200 ℃, and nitrogen is used as the drying gas.
9. Use of an antioxidant composition according to claim 1 as an ingredient in a carrier comprising one of an oily fluid carrier, an aqueous fluid carrier, an emulsion carrier, a solid carrier, either alone or in a mixture.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010133507.XA CN111228249A (en) | 2020-03-02 | 2020-03-02 | Antioxidant composition, preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010133507.XA CN111228249A (en) | 2020-03-02 | 2020-03-02 | Antioxidant composition, preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111228249A true CN111228249A (en) | 2020-06-05 |
Family
ID=70875116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010133507.XA Pending CN111228249A (en) | 2020-03-02 | 2020-03-02 | Antioxidant composition, preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111228249A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103619319A (en) * | 2011-06-28 | 2014-03-05 | 富士胶片株式会社 | Astaxanthin-containing composition, method for manufacturing same, and cosmetic |
| CN104114146A (en) * | 2012-02-24 | 2014-10-22 | 富士胶片株式会社 | Topical skin preparation and healthy skin cell activation agent |
| CN104244916A (en) * | 2012-03-28 | 2014-12-24 | 富士胶片株式会社 | Composition, and external preparation for the skin or functional food each containing said composition |
| CN109288052A (en) * | 2017-12-01 | 2019-02-01 | 天津地天科技发展有限公司 | A kind of health food manufacture craft for the four kinds of raw materials improving immunity and delaying senility |
| CN109820746A (en) * | 2019-04-08 | 2019-05-31 | 睿藻生物科技（苏州）有限公司 | A kind of lotion and preparation method thereof containing natural astaxanthin ester |
| CN109820837A (en) * | 2019-04-08 | 2019-05-31 | 睿藻生物科技（苏州）有限公司 | A kind of microcapsules of the ester containing natural astaxanthin and preparation method thereof |
-
2020
- 2020-03-02 CN CN202010133507.XA patent/CN111228249A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103619319A (en) * | 2011-06-28 | 2014-03-05 | 富士胶片株式会社 | Astaxanthin-containing composition, method for manufacturing same, and cosmetic |
| CN104114146A (en) * | 2012-02-24 | 2014-10-22 | 富士胶片株式会社 | Topical skin preparation and healthy skin cell activation agent |
| CN104244916A (en) * | 2012-03-28 | 2014-12-24 | 富士胶片株式会社 | Composition, and external preparation for the skin or functional food each containing said composition |
| CN109288052A (en) * | 2017-12-01 | 2019-02-01 | 天津地天科技发展有限公司 | A kind of health food manufacture craft for the four kinds of raw materials improving immunity and delaying senility |
| CN109820746A (en) * | 2019-04-08 | 2019-05-31 | 睿藻生物科技（苏州）有限公司 | A kind of lotion and preparation method thereof containing natural astaxanthin ester |
| CN109820837A (en) * | 2019-04-08 | 2019-05-31 | 睿藻生物科技（苏州）有限公司 | A kind of microcapsules of the ester containing natural astaxanthin and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10231907B2 (en) | Compositions for improving the health and appearance of skin | |
| KR101809451B1 (en) | Crickets for improved antioxidant, antiaging activity, skin beauty and cosmetic composition comprising the same | |
| FI86688B (en) | ANTIOXIDANTKOMPOSITIONER OCH ANVAENDNING AV DESSA. | |
| JPS6225190A (en) | Oxidation inhibitor composition and its use | |
| KR102092595B1 (en) | Cosmetic composition for UV screening comprising chlorella extract as an active ingredient | |
| JP6456357B2 (en) | Arthrobacter aziris extract, especially for use in cosmetics | |
| KR20070081192A (en) | Cosmetic compostion comprising liposome incorporating oryzanol, rice bran oil and phospholipid | |
| WO2016176485A1 (en) | Antioxidant compositions and methods of protecting skin, hair and nails against high energy blue-violet light | |
| KR101055963B1 (en) | Cosmetic composition for promoting exfoliation | |
| KR20140101570A (en) | Cosmetic composition for reinforcing skin barrier containing Persicaria hydropiper L. extract, and the liposome for enhancing transdermal delivery of Persicaria hydropiper L. extract | |
| KR101627051B1 (en) | Natural liposome comprising vitamin C, process for the preparation thereof, and cosmetic composition comprising the same | |
| CN113995693B (en) | Essence composition of liposome with anti-inflammatory effect, and preparation method and application thereof | |
| CN108836896B (en) | Stable fish oil emulsion for skin care products and cosmetics | |
| TR202008828A2 (en) | METHOD OF OBTAINING HIPPOPHAE RHAMNOIDES EXTRACT ENCAPSULATED WITH LIPOSOMAL TECHNOLOGY FOR USE IN COSMETIC FORMULAS | |
| KR101718190B1 (en) | Composition for protecting or curing human keratinocyte against UVB containing Extract of Carpomitra costata Stackhouse Batters as an active ingredient | |
| CN111228249A (en) | Antioxidant composition, preparation method and application | |
| KR102253702B1 (en) | Cosmetic composition comprising seaweed ingredients and seawater | |
| CA2968313A1 (en) | Preparations for suppressing or attenuating ocular irritancy | |
| KR102171924B1 (en) | External skin preparation for relaxing allergy comprising extract of wild-peach and method of producing the same | |
| KR100550965B1 (en) | Composition for promoting transdermal absorption of vitamins | |
| KR101363029B1 (en) | The cosmetic composition for anti-oxident and anti-aging of the skin comprising the Gelidium amansii, Undaria pinnatifida, wheat bud and Monarda horsemint | |
| KR101855210B1 (en) | Cosmetic composition containing eggplant seed ultrasonicating extract of fermented by aureobasidium pullulans | |
| KR20150008825A (en) | Cosmetic composition for reinforcing skin barrier containing isoquercitrin, and the liposome for enhancing transdermal delivery of isoquercitrin | |
| KR20210073558A (en) | AQUEOUS EXTRACT FROM CELLS OF FITZROYA CUPRESSOIDES (ALERCE) WITH ANTI-AGING AND SKIN REGENERATION PROPERTIES | |
| KR20050081753A (en) | Cosmetic composition for protecting skin comprising plant extract stabilized in nanoliposome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200605 |